Key result
Atrasentan matches ramipril in improving post-ischaemic myocardial function and reducing fibrosis in diabetic rat hearts.
Why the study?
Diabetes mellitus is associated with a specific cardiomyopathy, motivating a comparison of the cardioprotective effects of endothelin-A receptor blockade versus angiotensin-converting enzyme inhibition in experimental diabetes.
Does chronic endothelin-A receptor antagonism with atrasentan improve cardiac function and reduce fibrosis and oxidative stress as effectively as ACE inhibition with ramipril in diabetic rats?
Does chronic endothelin-A receptor antagonism with atrasentan improve cardiac function and reduce fibrosis and oxidative stress as effectively as ACE inhibition with ramipril in diabetic rats?
In experimental type 1 diabetic cardiomyopathy, endothelin-A receptor blockade with atrasentan provides cardioprotection against contractile dysfunction, fibrosis, and oxidative stress comparable to ACE inhibition with ramipril, though combining both agents offers no additive benefit.
Answers are grounded in this paper and cite their sources.
Atrasentan matches ramipril in diabetic rats; hypothesis-generating and leaves open clinical translation to human diabetic cardiomyopathy.
BACKGROUND AND PURPOSE: Diabetes mellitus is associated with a specific cardiomyopathy. We compared the cardioprotective effects of an endothelin-A receptor blocker (ET(A)-RB) with those of an angiotensin-converting enzyme inhibitor (ACE-I) in rats with streptozotocin (STZ)-induced diabetes. EXPERIMENTAL APPROACH: Diabetic rats were left untreated or received either the ET(A)-RB atrasentan or the ACE-I ramipril (each 3 mg kg(-1) per day) orally for 8 weeks. Isolated isovolumic heart function was studied during normoxia and in response to ischaemia-reperfusion. Cardiac fibrosis, tissue oxidative stress and tissue nitric oxide synthase (NOS) activity were determined. KEY RESULTS: Basal left ventricular systolic contractility was lower in diabetic compared to nondiabetic hearts and ET(A)-RB or ACE-I treatment significantly antagonised the decline. Following 15 min of no-flow ischaemia, reperfusion systolic function was depressed and left-ventricular end-diastolic pressure (LVEDP) was elevated in diabetic hearts. ET(A)-RB or ACE-I treatment significantly improved recovery of reperfusion systolic and diastolic function, without differences between groups. Hydroxyproline (an index of tissue fibrosis) and malondialdehyde (a measure of tissue oxidative stress) were elevated at the end of reperfusion in diabetic, compared to nondiabetic hearts. Either treatment reduced hydroxyproline and malondialdehyde to control level. Constitutive NOS activity was similar in nondiabetic and diabetic hearts and unaffected by ET(A)-RB or ACE-I treatment. CONCLUSIONS AND IMPLICATIONS: These results suggest that in experimental type 1 diabetes ET(A)-RB is as effective as an ACE-I in ameliorating myocardial functions during normoxia and ischaemia-reperfusion. Combining the two treatments neither afforded additive effects, nor diminished any protection effect seen with either drug.
No takes yet. Share an insight, caveat, or question.
Wölkart et al. (2007) studied Streptozotocin (STZ)-induced diabetes and diabetic cardiomyopathy in rats. Atrasentan (endothelin-A receptor blocker) vs. Ramipril (angiotensin-converting enzyme inhibitor) 3 mg kg(-1) per day orally, combination of both, or untreated diabetic and nondiabetic controls was evaluated on Isolated isovolumic heart function during normoxia and in response to 15 min of no-flow ischaemia-reperfusion. Oral atrasentan was as effective as ramipril in improving basal and post-ischaemic myocardial function and reducing fibrosis and oxidative stress in diabetic rat hearts.
Synapse has enriched 10 related papers. Consider them for comparative context: